Vaughan David Investments LLC IL boosted its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 197,314 shares of the company’s stock after purchasing an additional 1,330 shares during the quarter. Vaughan David Investments LLC IL’s holdings in Zoetis were worth $32,148,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its holdings in shares of Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the last quarter. Darwin Wealth Management LLC purchased a new position in shares of Zoetis in the third quarter worth approximately $31,000. First Personal Financial Services purchased a new position in shares of Zoetis in the third quarter worth approximately $33,000. Capital Performance Advisors LLP purchased a new position in shares of Zoetis in the third quarter worth approximately $33,000. Finally, Dunhill Financial LLC boosted its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the stock. Leerink Partners started coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Finally, Piper Sandler dropped their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus target price of $215.40.
Insider Activity at Zoetis
In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.
Zoetis Price Performance
Shares of ZTS stock opened at $165.51 on Tuesday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $74.12 billion, a P/E ratio of 30.26, a P/E/G ratio of 2.78 and a beta of 0.90. The company’s 50-day simple moving average is $166.30 and its two-hundred day simple moving average is $177.78. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, equities analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.
Zoetis Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.21%. Zoetis’s payout ratio is 36.56%.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Further Reading
- Five stocks we like better than Zoetis
- Learn Technical Analysis Skills to Master the Stock Market
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Earnings Per Share Calculator: How to Calculate EPS
- Price Targets on NVIDIA Rise in Front of Earnings
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.